NXNN - Nexeon MedSystems Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
4.9000
-1.5400 (-23.91%)
At close: 3:55PM EST
Stock chart is not supported by your current browser
Previous Close6.4400
Open5.3300
Bid0.00 x 0
Ask0.00 x 0
Day's Range4.9000 - 5.3300
52 Week Range0.3200 - 19.7500
Volume377
Avg. Volume198
Market Cap9.632M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.85
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
Trade prices are not sourced from all markets
  • GlobeNewswire24 days ago

    Nexeon MedSystems Announces Third Quarter 2018 Financial Results

    Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced today financial results for the third quarter of 2018. The Puerto Rico Science, Technology, and Research Trust has committed $100,000 in matching funds to support the first phase of the project. Consolidated revenues for the third quarter of 2018 were $1.98 million, a 0.4% decrease from pro forma consolidated revenues of $1.99 million for the third quarter of 2017.

  • GlobeNewswirelast month

    Nexeon MedSystems Receives Grant Matching Funds from the Puerto Rico Science, Technology, and Research Trust

    Nexeon MedSystems, Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced that it has received grant matching funds from the Puerto Rico Science, Technology, and Research Trust (“Trust”). The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) recently awarded a $830,000 grant to Nexeon’s wholly-owned subsidiary, Nexeon MedSystems Puerto Rico Operations Corporation (“NMPROC”, “Nexeon PR”, or “the Company”).

  • GlobeNewswire2 months ago

    Nexeon Announces Submission for FDA Innovation Challenge

    Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announces that it has submitted an application in response to the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder. Opioid Use Disorder (OUD), characterized by problematic symptoms of addiction to and withdrawal from opioids, is part of a public health crisis affecting more than 2 million Americans with significant physical, emotional, and cognitive impairment.

  • GlobeNewswire3 months ago

    Nexeon MedSystems Receives $830,000 grant from the National Institute of Neurological Disorders and Stroke

    Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced that it has received an $830,000 grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The grant award, received through its wholly-owned subsidiary Nexeon MedSystems Puerto Rico Operations Company Corporation (“NMPROC”), will support the development of novel cloud-based software to improve programming for deep brain stimulation. The NINDS intends to fund $1.5 million over 3 years, subject to annual review and approval, with the remaining funds directed towards clinical evaluation of the software’s performance.

  • ACCESSWIRElast year

    SeeThruEquity Issues Update on Nexeon MedSystems, Inc. (OTCQB: NXNN)

    NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...